Home Cart Sign in  
Chemical Structure| 714971-09-2 Chemical Structure| 714971-09-2

Structure of BMS-599626
CAS No.: 714971-09-2

Chemical Structure| 714971-09-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AC480 is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, > 100-fold to VEGFR2, c-Kit, Lck, MET etc.

Synonyms: AC480

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BMS-599626

CAS No. :714971-09-2
Formula : C27H27FN8O3
M.W : 530.55
SMILES Code : O=C(OC[C@H]1NCCOC1)NC2=CN3N=CN=C(NC4=CC5=C(N(CC6=CC=CC(F)=C6)N=C5)C=C4)C3=C2C
Synonyms :
AC480
MDL No. :MFCD10565678

Safety of BMS-599626

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of BMS-599626

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    HER1, IC50:20 nM

  • HER2/ErbB2

    HER2, IC50:30 nM

  • ErbB4

    HER4, IC50:190 nM

  • HER2

    HER2, IC50:30 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00093730 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, California ... More >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 Less <<
NCT00207012 HER2 or EGFR Expressing Advanc... More >>ed Solid Malignancies Less << Phase 1 Completed - France ... More >> Local Institution Villejuif Cedex, France Spain Local Institution Barcelona, Spain Less <<
NCT00095537 Cancer Metast... More >>ases Less << Phase 1 Completed - United States, Arizona ... More >> Local Institution Scottsdale, Arizona, United States Local Institution Tucson, Arizona, United States United States, California Local Institution Los Angeles, California, United States Less <<
NCT00979173 Glioma Phase 1 Completed - United States, North Carolina ... More >> The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT01245543 Solid Tumors Phase 1 Withdrawn(Clinical investigati... More >>ons have been discontinued and transfer to BMS 3/24/2015) Less << - United States, California ... More >> University of California San Francisco (UCSF) San Francisco, California, United States, 94118 United States, Texas South Texas Accelerated Research Therapeutics (START) San Antonio, Texas, United States, 78229 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.42mL

1.88mL

0.94mL

18.85mL

3.77mL

1.88mL

References

 

Historical Records

Categories